BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230919
DTEND;VALUE=DATE:20230922
DTSTAMP:20260516T072323
CREATED:20230726T074357Z
LAST-MODIFIED:20230726T074357Z
UID:37521-1695081600-1695340799@www.pharmajournalist.com
SUMMARY:7th IPF Summit
DESCRIPTION:FIbroGen’s recent Phase 3 trial failure for pamrevlumab exemplifies the critical time point the pulmonary fibrosis field is currently at as drug developers move through in-human to Phase 2 to Phase 3 trials to get the next disease-modifying drug to the patients in need. \nThe 7th IPF Summit (September 19-21 | Boston) returns at this crucial stage for the drug development and academic communities to come together to address R&D bottlenecks\, troubleshoot key discovery challenges\, and share exclusive data to accelerate the latest ideas and innovations in the IPF field and supercharge a new era of IPF therapeutics. \nIf you haven’t yet seen the line-up of 42+ expert speakers\, take a look at the full program in the event guide! \nAre you looking to address and solve challenges with IPF therapeutic development\, such as:   \n\nUnderstanding cell cross-talk in the lung pathobiology of IPF\, including epithelial and endothelial cells\nHarnessing precision medicine for IPF including patient selectivity\, combinational therapies\, and biomarkers\nWhether to incorporate imaging into your preclinical and clinical development and the potential of using imaging as an endpoint in IPF?\n\nThen this is the event for you! This is your unique opportunity to leverage knowledge from world-leading IPF industry experts and KOL academics on the latest developments to overcome\, discovery\, preclinical\, translational\, and clinical\, challenges of IPF therapeutic development for successful advancement of therapeutic candidates to in-human studies and beyond. \nJoin experts from the likes of Boehringer Ingelheim\, Genentech\, Pfizer\, AstraZeneca\, BMS\, Pliant\, Galecto\, Vicore\, Avalyn\, Pieris\, Moderna\, Takeda and more who have already saved their places at the meeting. \nSee pricing and registration options here!
URL:https://www.pharmajournalist.com/event/7th-ipf-summit/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR